Introduction

Metformin is an orally administered drug that is recommended as first-line pharmacological treatment for type 2 diabetes (T2D) in almost all diabetic and endocrine scientific society guidelines [1-2]. Previously known that the main anti-hyperglycemia effect of metformin through inhibition of the hepatic glucose output but recently there is increasing evidence that the primary effect of metformin may resides in the human gut [3-4]. Fineman and their colleagues show clearly that metformin effect on the glycemic control through the gut may be stronger than its effect systemically through its effect on hepatic glucose output and they develop what is called delayed release metformin Met DR tablets [4].

The major advantages of metformin are improvement of peripheral insulin sensitivity, controlling hyperglycemia with low risk of hypoglycemia, and without inducing weight gain, actually there is evidence of promoting weight loss and cardiovascular safety [5-7]. Similarly, there is growing body of evidence that metformin is an antioxidant that reduce cancer risk [8].

Metformin induces modest weight loss most likely through Lipid through an AMP-activated protein kinase pathway [11]. However, most studies have review the effect of 6 months or more of metformin on weight and lipid profile while the short term effect for 3 months was not extensively studied, that’s why our study focus on this reasonably deficient area of metformin effect.

Effect of Metformin on Weight and Biochemical Indices in over Weight and Obese Diabetics

1Eman Z Younis, 2,3Adela H Elamami, 4Rugaia MEI-Salem

1Department of Biology, Faculty of Education-Ghemines, University of Benghazi, Benghazi, Libya
2Department of Medicine, Faculty of Medicine, University of Benghazi, Benghazi, Libya
3The Endocrine Unit, Hauari General Hospital, Benghazi, Libya
4Department of Nutrition Artificial Kidney Unit, BMC Benghazi, Libya

*Correspondence to: Eman Z Younis, Department of Biology, Faculty of Education-Ghemines, University of Benghazi, Benghazi, Libya, E-mail: Eman.younis@uob.edu.ly

Received: 23 February 2021; Accepted: 16 March 2021; Published: 25 March 2021

Copyright: © 2021 Younis EZ. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

An effect of metformin on weight and biochemical parameter for 6 month or longer is extensively studied while the effect of only 3 months is not fully elaborated. In our retrospective study we collect and analyze data for the effect of metformin (3 months) on obese newly diagnosed diabetic on diet control (Mediterranean diet with reduce total calories intake) following a registered Nutritionist at Elkodes clinic. We include data of all overweight and obese newly diagnosed diabetics before and after 3 months period of starting metformin in addition to diet control. Patients on anti-lipid or weight reduction therapy and patient with known liver or renal disease were excluded. Paired T test was used. The mean weight, total cholesterol, triglyceride, LDL-C and as expected HbA1c (72.04 Kg, 182.4 mg/dl, 135 mg/dl, 85.6 mg/dl, 6.1) was significantly lower after metformin compared to before therapy (83.6 Kg, 208.5 mg/dl, 169 mg/dl, 113 mg/dl, 7.9) respectively. Renal and liver functions were not statistically different. Our study shows that metformin can have significant favorable effect on weight and lipid profile even for (3 months) use without effect on liver function. Most previous evidence demonstrates the effect of metformin after 6 months or longer.

Keywords: Metformin effect; Obesity; Diabetes.
Patients and Method

Study design

A retrospective study involving data from the file notes of registered nutritionist from 2012-2015 at Ekods clinic. We include data of all overweight and obese newly diagnosed diabetics before and after 3 months period of starting metformin in addition to diet control.

Exclusion criteria

Patients on anti-lipid or weight reduction therapy and patient with known liver or renal disease were excluded.

Data collection

Weight, total cholesterol (TC), Triglyceride (TG), Low Density lipoprotein–cholesterol (LDL-C), Renal function test (RFT), Liver function test (LFT) and HbA1c before and after 3 months of metformin was collected from the file notes in addition to demographic data.

Data Analysis

The data was analyzed using Statistical package for the social science (SPSS) version 21, paired T test was used to detect the difference in the weight and biochemical indices (T cholesterol, Triglyceride, LDL-C, RFT, LFT and HbA1c) before and after starting metformin. Pearson correlation was used to correlate the dose of metformin and these variables.

Results

Out of all data files searched only 110 patients they fill full the inclusion and exclusion criteria. Eighty six were females (78.1%) and twenty four males (21.8%) [Figure 1].

A total of 101 were on low dose metformin (500mg /d) and nine patients on moderate dose (1000mg/d) [Figure 2].

Figure 1: The percentage of the patients in the sample according to gender

Table 1: The mean age of the patients was 37.2 +/- 8.5SD and the range was from (19-58) years

| Sex of the patient | Age of the patients |
|--------------------|---------------------|
| Valid              | 110                 |
| Missing            | 0                   |
| Mean               | 37.2                |
| Median             | 37.5                |
| Std. Deviation     | 8.54                |

There were statistically significant reduction of weight and metabolic parameters after 3 months of metformin therapy as compare to before therapy, weight (83.6 +/- 10.4, 72 +/-9.1 , p value=.000) , total cholesterol (208.5 +/- 49.7, 182.4 +/-40.85 , p value=.000) , LDL –cholesterol (113.3 +/- 31.49 , 85.7 +/- 23.2 (p value=.000) , Triglyceride TG ( 169.1 +/- 78.9 , 135 +/- 52.5, p value=.000 ) and as expected HbA1c (7.9 +/- 1.2, 6.1 +/- 1.4, p value=.000 ).

Figure 3: The mean level of the weight and biochemical indices before and after 3 months of metformin therapy

While there were no statistically significant difference before and after 3 month of metformin therapy in the serum creatinine (0.55 +/- 0 .2, 0.51 +/- 0.2, p value =0.28), liver enzymes, AST (20.2 +/- 6.5, 19.8+/-.765, p value = 0.693), ALT (19.95 +/- 7.5, 20.1+/-.6.6, p value=0.835).
Figure 4: The mean level of Renal and liver function before and after 3 month of metformin therapy

The mean ALT/AST Ratio was slightly increased after metformin therapy (1.2+/-.7 SD) than before therapy (1.1+/-.64 SD) [Table 2].

Table 2: ALT/AST ratio before and after metformin therapy

|                           | N  | Minimum | Maximum | Mean   | Std. Deviation |
|---------------------------|----|---------|---------|--------|----------------|
| ALT/AST ratio before      | 110| .20     | 4.30    | 1.1167 | .64274         |
| metformin therapy         |    |         |         |        |                |
| ALT/AST ratio after       | 110| .24     | 4.50    | 1.2162 | .72011         |
| metformin therapy         |    |         |         |        |                |

Table 3: Significance of ALT/AST ratio before and after metformin therapy

| Paired Differences | t  | df | Sig. (2-tailed) |
|--------------------|----|----|----------------|
| Mean               |    |    |                |
| Std. Deviation     |    |    |                |
| Std. Error Mean    |    |    |                |
| 95% Confidence     |    |    |                |
| Interval of the    |    |    |                |
| Difference          |    |    |                |
| Lower              | .09945 | 1.26074 | .12021 | 4.50 | .827 | 109 | .410 |
| Upper              |       |        |          |      |      |      |      |

In our study there was no significant correlation of weight and biochemical indices (T cholesterol, LDL-C, TG, AST, ALT, creatinine) with dose of metformin used while HbA1C was significantly correlated with the dose (Pearson’s R = 0.231, p value = 0.015). But the limitation of result of correlation that most of the patients were on low dose metformin and small percentage on moderate dose and no patient on high dose.

Discussion

Our study demonstrate significant reduction in weight of the patients on use of metformin for 3 months (83.6 +/- 10.4, 72 +/-9.1, p value = .000). This is in concordance with result of Szu Han Lin, et al. (2018) which they found that mean body weight changed from 69 kilograms to 68.3 kilograms (p = 0.01) [12]. However, this achieved on longer time of treatment (12 months period) than our study.

Seifarth and their colleagues (2013) evaluate the effectiveness of high dose metformin on weight in 154 obese non diabetics over 6 month’s period. They found that the mean weight loss in the metformin treated group was 5.8 ± 7.0 kg (5.6 ± 6.5%). Untreated controls gained 0.8 ± 3.5 kg (0.8 ± 3.7%) on average. Patients with severe insulin resistance lost significantly more weight as compared to insulin sensitive patients. The percentage of weight loss was independent of age, sex or BMI [13].

The effect of metformin on lipids was shown in a study of Szu Han Lin, et al (2018) which conclude that after initiating metformin therapy, LDL-C was significantly reduced from 111 mg/dl to 102 mg/dl (p<0.001), TG was reduced from 132 mg/dl to 122 mg/dl (p =0.046), HDL-C increased from 45.1 mg/dl to 46.9 mg/dl (p =0.02) and mean HbA1c was reduced from 8% to6.47% (p <0.001) at 6 months to 12 months [12]. These finding are comparable to our finding which shows that Total cholesterol was significantly reduced from (208.5 mg/dl to 182.4 mg/dl , p value =.000), LDL -cholesterol (113.3 mg/dl to 85.7 mg/dl , p value = .000), Triglyceride TG (169.1 mg/dl to 135 mg/dl , p value =.000) and as expected HbA1c (7.9 +/- 1.2 , 6.1 +/- 1.4 , p value =.000). But what interesting in our finding that these changes in weight and lipid profile was seen after just 3 months of low or moderate dose of metformin. The existing evidence that hyper triglyceridemia and diminished HDL-C require a longer therapeutic duration to counteract than lowering LDL-C which usually 6-12 months duration is contradicted by our finding which support the rationale that even three month of metformin therapy can lead to significant triglyceride changes [14].

Conclusion

The study shows that metformin can have significant favorable effect on weight and lipid profile even on for (3 months) use. Most previous evidence demonstrates the effect of metformin after 6 months or longer.

Acknowledgements

The authors acknowledge that there is no any financial support or grants for this work.
References
1. American Diabetes Association. “Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020”. Diabetes Care 43 (Suppl.1 2020): S98-S110.
2. International Diabetes Federation. “Managing Type 2 Diabetes In Primary Care”: (2017).
3. Song R. “Mechanism of Metformin: A Tale of Two Sites”. Diabetes Care 39(2016) 39: 187-189.
4. Buse JB, DeFronzo RA, Rosenstock J et al. “The primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-week dose-ranging studies”. Diabetes Care 39(2016): 198-205.
5. Malin SK, Gerber R, Chipkin SR, Braun B. “Independent and combined effects of exercise training and metformin on insulin sensitivity in individuals with prediabetes”. Diabetes Care 35 (2012): 131-136.
6. Yanovski JA, Krakoff J, Salaita CG, McDuffie JR, Kozlosky M et al. “Effects of Metformin on Body Weight and Body Composition in Obese Insulin-Resistant Children”. Diabetes 60 (2011): 477-485.
7. American Diabetes Association. “Implications of the United Kingdom Prospective Diabetes Study”. Diabetes Care 23(suppl1 2002): s28-s32.
8. Kasznicki J, Slwińska A, Drzewoski J. “Metformin in cancer prevention and therapy”. Ann Transl Med 2 (2014): 57.
9. Yanovski JA, Krakoff J, Salaita CG, McDuffie JR, Kozlosky M et al. “Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial”. Diabetes 60(2011): 477-485.
10. Desilets AR, Dhakal-Karki S, Dunican KC. “Role of metformin for weight management in patients without type 2 diabetes”. Ann Pharmacother 42 (2008): 817-26.
11. Xu T, Brandmaier S, Messias AC, Herder C, Draisma HH et al. “Effects of metformin on metabolite profiles and LDL cholesterol in patients with type 2 diabetes”. Diabetes Care 38 (2015): 1858-1867.
12. Lin SH, Cheng PC, Tu ST, Hsu SS, Cheng YC et al. “Effect of metformin monotherapy on serum lipid profile in statin-naive individuals with newlydiagnosed type 2 diabetes mellitus: a cohort study”. Peer J 6(2018): e4578.
13. Seifarth C, Schehler B, Schneider HJ. “Effectiveness of Metformin on Weight Loss in Non-Diabetic Individuals with Obesity”. Exp Clin Endocrinol Diabetes 121(2013): 27-31.
14. Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R et al. “The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial”. Ann Transl Med 142(2005): 611-619.

Citation: Younis EZ. “Effect of Metformin on Weight and Biochemical Indices in over Weight and Obese Diabetics”. DOI:10.47755/J Clin Diabetes Obes.2021.1.004